EX-99.1 2 tm2522626d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2025 Financial Results Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue ─────────────────────────────────────────────────────────────────────────────────────────────── Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestiture Company reaffirms full year 2025 revenue guidance of $165 to $172 million NASHVILLE, Tennessee, August 5, 2025, - Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2025. Jerrell Shelton, CEO of Cryoport, commented, “Cryoport delivered strong, double-digit growth across all revenue streams within Life Sciences Services in the second quarter, increasing 21% year-over-year and accounting for 54% of total re…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
CryoPort, Inc.
CYRXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 5, 2025, Cryoport, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1.…
Company context
Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."